Business, energy, technology, markets and global industry news from Business News Today

CANOPY-HCH-3

PharmaDeviceNews CANOPY-HCH-3
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

BioMarin seeks FDA approval for Voxzogo in hypochondroplasia after Phase 3 success

BioMarin presents Voxzogo skull growth research and Phase 3 hypochondroplasia data. Examine clinical evidence, FDA reviews and 2027 prospects.

Read More
Pharma & Biotech

VOXZOGO added 2.33 cm a year in Phase 3. Can BioMarin turn that growth signal into a new FDA indication?

BioMarin’s VOXZOGO met its Phase 3 hypochondroplasia endpoint with a 2.33 cm/year growth velocity benefit as an FDA filing moves forward.

Read More
Representative image of a pediatric growth assessment in a clinical setting. BioMarin’s latest VOXZOGO data highlight how long-term achondroplasia treatment is moving beyond height gains toward arm span, bone health, and broader skeletal development outcomes.
Pharma & Biotech

Why BioMarin’s VOXZOGO update matters ahead of hypochondroplasia Phase 3 data

VOXZOGO is no longer just a height story. BioMarin now needs long-term data to support a broader skeletal dysplasia strategy.

Read More